Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.
Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
Eur J Clin Invest. 2021 May;51(5):e13449. doi: 10.1111/eci.13449. Epub 2020 Nov 23.
Early diagnosis of cardiac amyloidosis (CA) is warranted to initiate specific treatment and improve outcome. The amyloid light chain (AL) and inferior wall thickness (IWT) scores have been proposed to assess patients referred by haematologists or with unexplained left ventricular (LV) hypertrophy, respectively. These scores are composed of 4 or 5 variables, respectively, including strain data.
Based on 2 variables common to the AL and IWT scores, we defined a simple score named AMYLoidosis Index (AMYLI) as the product of relative wall thickness (RWT) and E/e' ratio, and assessed its diagnostic performance.
In the original cohort (n = 251), CA was ultimately diagnosed in 111 patients (44%). The 2.22 value was selected as rule-out cut-off (negative likelihood ratio [LR-] 0.0). In the haematology subset, AL CA was diagnosed in 32 patients (48%), with 2.36 as rule-out cut-off (LR- 0.0). In the hypertrophy subset, ATTR CA was diagnosed in 79 patients (43%), with 2.22 as the best rule-out cut-off (LR- 0.0). In the validation cohort (n = 691), the same cut-offs proved effective: indeed, there were no patients with CA in the whole population or in the haematology or hypertrophy subsets scoring < 2.22, <2.36 or < 2.22, respectively.
The AMYLI score (RWT*E/e') may have a role as an initial screening tool for CA. A < 2.22 value excludes the diagnosis in patients undergoing a diagnostic screening for CA, while a < 2.36 and a < 2.22 value may be better considered in the subsets with suspected cardiac AL amyloidosis or unexplained hypertrophy, respectively.
早期诊断心脏淀粉样变性(CA)是启动特异性治疗并改善预后的关键。淀粉样轻链(AL)和下壁厚度(IWT)评分分别用于评估血液科转诊患者或不明原因左心室(LV)肥厚患者。这两个评分分别由 4 或 5 个变量组成,包括应变数据。
基于 AL 和 IWT 评分共有的 2 个变量,我们定义了一个名为 AMYLoidosis Index(AMYLI)的简单评分,即相对壁厚度(RWT)和 E/e'比值的乘积,并评估了其诊断性能。
在原始队列(n=251)中,最终诊断为 111 例(44%)CA。选择 2.22 作为排除截断值(阴性似然比[LR-]为 0.0)。在血液学亚组中,诊断出 32 例(48%)AL CA,以 2.36 作为排除截断值(LR-为 0.0)。在肥厚亚组中,诊断出 79 例(43%)ATTR CA,以 2.22 作为最佳排除截断值(LR-为 0.0)。在验证队列(n=691)中,相同的截断值仍然有效:实际上,在整个人群或血液学或肥厚亚组中,没有 CA 患者的评分<2.22、<2.36 或<2.22。
AMYLI 评分(RWT*E/e')可能作为 CA 的初始筛查工具。<2.22 值可排除 CA 诊断患者,<2.36 和<2.22 值可分别更好地考虑疑似心脏 AL 淀粉样变性或不明原因肥厚的亚组患者。